Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 
Chinese biotech company Bliss Biopharmaceutical (BlissBio) is reportedly considering a Hong Kong initial public offering (IPO) that could raise at least $150 million, according to Bloomberg sources. The Hangzhou-based cancer drug developer is working with financial advisers to evaluate the listing, although final decisions have yet to be made and the IPO size could still change. There is also a possibility the company may postpone or cancel the plan.
Founded in 2017, BlissBio focuses on antibody-drug conjugates (ADCs) that specifically target tumors. The company currently has multiple therapies in early-stage clinical trials, including Phase 1 and Phase 2 studies, as stated on its website. ADCs are a cutting-edge treatment combining antibodies with cancer-killing agents to selectively target cancer cells, offering potential breakthroughs in oncology.
Investor interest in China's biotech sector remains strong, especially for innovative oncology firms. A recent example is Duality Biotherapeutics Inc (HK:9606), which saw its shares nearly double after its Hong Kong IPO last month, reflecting growing confidence in homegrown pharmaceutical innovation.
If successful, BlissBio’s IPO would join a wave of Chinese biotech listings on the Hong Kong Stock Exchange, which has become a favored venue for healthcare companies seeking capital to fund clinical trials and expand their R&D pipelines. With increasing demand for novel cancer therapies in China and globally, the market is watching closely to see whether BlissBio moves forward with the offering.
